Table 1.
Baseline patients characteristics stratified by status of clinical trial participation
| Characteristic | Clinical trial participants (n=49) | Matched clinical trial non-participants (n=49) | p-value |
|---|---|---|---|
| Age (yr) | |||
| Median (range) | 64 (22-79) | 64 (24-77) | 0.8 |
| Mean±SD | 61±11 | 62±10 | |
| Sex | |||
| Male | 33 (67) | 33 (67) | > 0.99 |
| Female | 16 (33) | 16 (33) | |
| Tumor histology | > 0.99 | ||
| Clear cell histology | 42 (86) | 42 (86) | |
| Non-clear cell | 7 (14) | 7 (14) | |
| Presence of sarcomatoid component | 3 (6) | 4 (8) | 0.84 |
| Past nephrectomy | 45 (92) | 45 (92) | > 0.99 |
| Prior systemic therapy | 8 (16) | 8 (16) | > 0.99 |
| Lung metastasis | 38 (78) | 40 (82) | 0.62 |
| Liver metastasis | 12 (24) | 17 (35) | 0.27 |
| Bone metastasis | 18 (37) | 16 (33) | 0.67 |
| ≥ 2 metastatic sites | 41 (84) | 44 (90) | 0.8 |
| Sunitinib induced HTN | 27 (45) | 27 (45) | > 0.99 |
| Sunitinib dose reduction/treatment interruption | 20 (41) | 20 (41) | > 0.99 |
| Users of ASIs | 18 (37) | 18 (37) | > 0.99 |
| Users of bisphosphonates | 11 (22) | 2 (4) | 0.04 |
| Heng risk stratification | |||
| Favorable | 12 (25) | 12 (25) | > 0.99 |
| Intermediate | 29 (59) | 29 (59) | |
| Poor | 8 (16) | 8 (16) | |
| Pre-treatment NLR > 3 | 27 (55) | 27 (55) | > 0.99 |
| Smoking status | |||
| Never | 19 (39) | 20 (41) | 0.97 |
| Past | 18 (37) | 18 (37) | |
| Active | 12 (24) | 11 (22) | |
| Subsequent therapy lines | |||
| Second line | 24 (49) | 21 (43) | 0.7 |
| Third line | 4 (8) | 3 (6) | 0.85 |
Values are presented as number (%) unless otherwise indicated. SD, standard deviation; HTN, hypertension; ASIs, angiotensin system inhibitors; NLR, neutrophil to lymphocyte ratio.